IBJNews

Analysts: Investors wrong to dump Endocyte

Back to TopCommentsE-mailPrintBookmark and Share

Investors on Friday dumped shares of West Lafayette-based Endocyte Inc. after an independent analysis said an experimental lung cancer drug is unlikely to be declared superior to existing chemotherapy. But two analysts say, to the contrary, the analysis shows the prospects for Endocyte’s drug are as good as ever.

Endocyte is studying the drug vintafolide in patients with non-small-cell lung cancer and comparing its effects to an existing chemotherapy drug called docetaxel.

Vintafolide has already shown strong effects against late-stage ovarian cancer, and Endocyte has moved to win regulators’ approval for that disease in Europe. But Endocyte also thinks vintafolide could work against other types of cancer, such as lung and breast.

What Endocyte reported Friday were the results of a mid-stage analysis of a clinical trial by the Data Safety Monitoring Board. The board conducted a futility analysis of vintafolide and found that it’s at least good enough for doctors to continue giving it to patients.

What the board also found was that it is unlikely that vintafolide alone will show itself superior to docetaxel at extending the progression-free survival times of lung cancer patients. But as Wall Street analysts pointed out, the trial has enough patients to show superiority only if vintafolide extends patients’ progression-free survival 50 percent longer than Doxil.

“We are surprised at the stock’s negative reaction,” wrote Wedbush Securities analyst Gregory White in a Friday note to investors. Endocyte shares fell more than 14 percent on Friday and have fallen even more on Monday to below $10 per share—their lowest level since March.

Vintafolide could still prove superior to docetaxel, and yet not be able to show that superioty in this particular clinical trial. It’s also possible that vintafolide could end up being inferior to Doxil, wrote RBC Capital Markets analyst Adnan Butt in a Friday note to investors.

The same goes for another part of Endocyte’s study, which compares a combined dose of both vintafolide and docetaxel against docetaxel alone. Docetaxel was once sold under the brand name Taxotere.

“For either the combination [dose] arm or the single agent vintafolide arm to show superiority over docetaxel was a high bar especially at the interim” point in the clinical trial,” Butt wrote.

Butt and White said the key positives from the analysis are that vintafolide is safe enough and at least close enough to docetaxel in effectiveness for the trial to keep going. And, they noted, the combination of vintafolide and docetaxel could still prove to be superior to docetaxel alone.

They both reiterated their positive recommendations on Endocyte’s stock.

For its part, Endocyte said it was encouraged by the board’s analysis of vintafolide.

"We are very pleased that our combination therapy of vintafolide and docetaxel successfully passed the pre-defined interim analysis, and we look forward to announcing the top-line results of this trial early next year," said Dr. Binh Nguyen, vice president of clinical development at Endocyte, in a prepared statement.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Can your dog sign a marriage license or personally state that he wishes to join you in a legal union? If not then no, you cannot marry him. When you teach him to read, write, and speak a discernible language, then maybe you'll have a reasonable argument. Thanks for playing!

  2. Look no further than Mike Rowe, the former host of dirty jobs, who was also a classically trained singer.

  3. Current law states income taxes are paid to the county of residence not county of income source. The most likely scenario would be some alteration of the income tax distribution formula so money earned in Marion co. would go to Marion Co by residents of other counties would partially be distributed to Marion co. as opposed to now where the entirety is held by the resident's county.

  4. This is more same-old, same-old from a new generation of non-progressive 'progressives and fear mongers. One only needs to look at the economic havoc being experienced in California to understand the effect of drought on economies and people's lives. The same mindset in California turned a blind eye to the growth of population and water needs in California, defeating proposal after proposal to build reservoirs, improve water storage and delivery infrastructure...and the price now being paid for putting the demands of a raucous minority ahead of the needs of many. Some people never, never learn..

  5. I wonder if I can marry him too? Considering we are both males, wouldn't that be a same sex marriage as well? If they don't honor it, I'll scream discrimination just like all these people have....

ADVERTISEMENT